3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
27
Neoplasm Metastasis
5
Advanced Solid Tumors
5
Stomach Neoplasms
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Advanced Solid Tumors (Excluding Breast Cancer)
2
Urologic Diseases
1
Spinocerebellar Degenerations
1
Solid Tumor Cancer
1
Small Cell Lung Carcinoma
1
Sarcoma, Ewing
1
Sarcoma, Alveolar Soft Part
1
Sarcoma
1
Renal Insufficiency
1
Refractory Solid Tumors
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Lung Neoplasms
1
Liver Neoplasms
1
Liver Diseases
1
Kidney Neoplasms
1
Kidney Diseases
1
Head and Neck Neoplasms
1
HER2 IHC3+ Advanced Colorectal Cancer
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Desmoid Tumors
1
Interventions
trifluridine tipiracil drug combination
1
reolysin
1
atezolizumab
1
Gemcitabine
1
Albumin-Bound Paclitaxel
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Anal Cancer Metastatic
×
trifluridine tipiracil drug combination
×
Clear all
NCT07280377
2026-05-19
GOBLET
Oncolytics Biotech
Phase 1/2
Active not recruiting
122 enrolled